(Q48785786)

15 February 2018

title

Adding human menopausal gonadotrophin to antagonist protocols - is there a benefit? (English)

1 reference

15 February 2018

author name string

Meredith Martin-Johnston

1

1 reference

15 February 2018

Angeline N Beltsos

2

1 reference

15 February 2018

H Edward Grotjan

3

1 reference

15 February 2018

Meike L Uhler

4

1 reference

15 February 2018

publication date

1 August 2007

1 reference

15 February 2018

Reproductive BioMedicine Online

published in

1 reference

15 February 2018

volume

15

1 reference

15 February 2018

issue

2

1 reference

15 February 2018

page(s)

161-168

1 reference

15 February 2018

Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized cont

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

The role of luteinizing hormone in folliculogenesis and ovulation induction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Follitropin-α versus human menopausal gonadotropin in an in vitro fertilization program

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Evidence for different aetiologies of low estradiol response to FSH: age-related accelerated luteinization of follicles or presence of ovarian autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Does the addition of luteinizing hormone in ovarian stimulation protocols improve the outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Ovarian stimulation: from basic science to clinical application.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Improved oocyte quality is obtained with follicle stimulating hormone alone than with follicle stimulating hormone/human menopausal gonadotrophin combination.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Accumulation of human chorionic gonadotrophin in the serum of patients during in-vitro fertilization treatment cycles with Pergonal

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Effect of highly purified urinary follicle-stimulating hormone on oocyte and embryo quality

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960704-3

7 January 2021

10.1016/S1472-6483(10)60704-3

Identifiers

DOI

1 reference

15 February 2018

PubMed ID

17697491

1 reference

15 February 2018